Showing 1 to 12 of 43 results
Huntington's Disease Progression Slowed by 75% in Clinical Trial
British researchers announced a 75% reduction in Huntington's disease progression over 36 months in a clinical trial of 29 patients using a new gene therapy, AMT-130, developed with UniQure.
Huntington's Disease Progression Slowed by 75% in Clinical Trial
British researchers announced a 75% reduction in Huntington's disease progression over 36 months in a clinical trial of 29 patients using a new gene therapy, AMT-130, developed with UniQure.
Progress
16% Bias Score
UniQure's Gene Therapy Shows Promise in Slowing Huntington's Disease Progression
A Phase 1/2 study by uniQure showed a 75% reduction in Huntington's disease progression in patients receiving a high dose of AMT-130 gene therapy after 36 months, marking a potential breakthrough in treating this currently incurable condition.
UniQure's Gene Therapy Shows Promise in Slowing Huntington's Disease Progression
A Phase 1/2 study by uniQure showed a 75% reduction in Huntington's disease progression in patients receiving a high dose of AMT-130 gene therapy after 36 months, marking a potential breakthrough in treating this currently incurable condition.
Progress
52% Bias Score
Huntington's Disease Treatment Shows 75% Slowdown in Clinical Progression
A new gene therapy has demonstrated a 75% slowdown of Huntington's disease progression in a clinical trial, offering a potential life-extending treatment for those affected.
Huntington's Disease Treatment Shows 75% Slowdown in Clinical Progression
A new gene therapy has demonstrated a 75% slowdown of Huntington's disease progression in a clinical trial, offering a potential life-extending treatment for those affected.
Progress
48% Bias Score
Multiply Labs and Universal Robots Partner to Automate Cell Therapy Production
Multiply Labs, a San Francisco startup, partnered with Universal Robots to automate cell therapy production, aiming to reduce costs and increase manufacturing scale of these expensive and complex treatments.
Multiply Labs and Universal Robots Partner to Automate Cell Therapy Production
Multiply Labs, a San Francisco startup, partnered with Universal Robots to automate cell therapy production, aiming to reduce costs and increase manufacturing scale of these expensive and complex treatments.
Progress
56% Bias Score
Innovative HIV Cure Approaches Show Promise in Trials
Building on the success of stem cell transplants, innovative HIV cure approaches like combination therapies (including mRNA delivery and novel antibodies) and gene therapies are showing promise in trials, particularly in children and early-diagnosed adults, offering hope for a widely accessible cure...
Innovative HIV Cure Approaches Show Promise in Trials
Building on the success of stem cell transplants, innovative HIV cure approaches like combination therapies (including mRNA delivery and novel antibodies) and gene therapies are showing promise in trials, particularly in children and early-diagnosed adults, offering hope for a widely accessible cure...
Progress
36% Bias Score
Newborn's Stiffness Leads to Devastating Rare Disease Diagnosis
Six-month-old Madeline Norton from Massapequa, New York, received a devastating diagnosis of Pantothenate Kinase-Associated Neurodegeneration (PKAN), a rare genetic disorder giving her a life expectancy of only 10-15 years; her only initial symptom was stiffness.
Newborn's Stiffness Leads to Devastating Rare Disease Diagnosis
Six-month-old Madeline Norton from Massapequa, New York, received a devastating diagnosis of Pantothenate Kinase-Associated Neurodegeneration (PKAN), a rare genetic disorder giving her a life expectancy of only 10-15 years; her only initial symptom was stiffness.
Progress
52% Bias Score
Huntington's Disease Treatment Shows Significant Progress
British researchers announced a new gene therapy that slowed Huntington's disease progression by 75% in a clinical trial of 29 patients over 36 months, offering a potential breakthrough for the 6,000 individuals in France affected by this neurodegenerative disorder.
Huntington's Disease Treatment Shows Significant Progress
British researchers announced a new gene therapy that slowed Huntington's disease progression by 75% in a clinical trial of 29 patients over 36 months, offering a potential breakthrough for the 6,000 individuals in France affected by this neurodegenerative disorder.
Progress
36% Bias Score
Experimental Gene Therapy Shows Significant Slowdown in Huntington's Disease Progression
A Phase 1/2 study by uniQure showed that a high dose of their gene therapy, AMT-130, slowed Huntington's disease progression by 75% in patients after 36 months, marking a potential breakthrough for the currently incurable disease.
Experimental Gene Therapy Shows Significant Slowdown in Huntington's Disease Progression
A Phase 1/2 study by uniQure showed that a high dose of their gene therapy, AMT-130, slowed Huntington's disease progression by 75% in patients after 36 months, marking a potential breakthrough for the currently incurable disease.
Progress
40% Bias Score
Russian Scientists Make Breakthroughs in Cancer Treatment and Rare Disease Therapies
Over the past 10 years, a Russian research center has made significant advancements, including developing new cancer therapies, synthesizing expensive rare disease drugs faster than foreign competitors, and creating AI programs to expedite vaccine development.
Russian Scientists Make Breakthroughs in Cancer Treatment and Rare Disease Therapies
Over the past 10 years, a Russian research center has made significant advancements, including developing new cancer therapies, synthesizing expensive rare disease drugs faster than foreign competitors, and creating AI programs to expedite vaccine development.
Progress
60% Bias Score
Mecklenburg-Vorpommern Funds €8.2 Million for Cell and Gene Therapy Platform
The state of Mecklenburg-Vorpommern in Germany is providing €8.2 million in funding from the European Regional Development Fund (EFRE) to support the development of a cell and gene therapy platform by a research consortium involving Miltenyi Biotec, RoweMed AG, and the University of Rostock.
Mecklenburg-Vorpommern Funds €8.2 Million for Cell and Gene Therapy Platform
The state of Mecklenburg-Vorpommern in Germany is providing €8.2 million in funding from the European Regional Development Fund (EFRE) to support the development of a cell and gene therapy platform by a research consortium involving Miltenyi Biotec, RoweMed AG, and the University of Rostock.
Progress
24% Bias Score
Scientists Synthesize and Transfer 1.14-Million Base Pair Human Genome Fragment
Researchers at Tianjin University synthesized a 1.14-million base pair human genome fragment from the AZFa region of the Y chromosome and successfully transferred it into mouse cells using a novel SynNICE system, overcoming challenges in handling repetitive DNA sequences and large-segment transfer, ...
Scientists Synthesize and Transfer 1.14-Million Base Pair Human Genome Fragment
Researchers at Tianjin University synthesized a 1.14-million base pair human genome fragment from the AZFa region of the Y chromosome and successfully transferred it into mouse cells using a novel SynNICE system, overcoming challenges in handling repetitive DNA sequences and large-segment transfer, ...
Progress
32% Bias Score
FDA Director Prasad Resigns, Then Returns Amidst Controversy
Vinay Prasad, the FDA's Center for Biologics Evaluation and Research director, resigned on July 30th following criticism of the agency's handling of a gene therapy linked to patient deaths and attacks from Laura Loomer, but returned to his position on August 10th at the FDA's request.
FDA Director Prasad Resigns, Then Returns Amidst Controversy
Vinay Prasad, the FDA's Center for Biologics Evaluation and Research director, resigned on July 30th following criticism of the agency's handling of a gene therapy linked to patient deaths and attacks from Laura Loomer, but returned to his position on August 10th at the FDA's request.
Progress
40% Bias Score
Showing 1 to 12 of 43 results